ストックスクリーナーアプリを入手
169.40
1.85%
-3.19
アフターアワーズ：
168.38
-1.02
-0.60%
前日終値:
$172.59
開ける：
$171.19
24時間の取引高:
3.26M
Relative Volume:
1.19
時価総額：
$48.55B
収益：
$20.87B
当期純損益:
$1.50B
株価収益率:
32.33
EPS:
5.24
ネットキャッシュフロー:
$2.59B
1週間 パフォーマンス:
-1.16%
1か月 パフォーマンス:
+0.37%
6か月 パフォーマンス:
-23.97%
1年 パフォーマンス:
-26.97%
1日の値動き範囲:
$167.97
$171.84
1週間の範囲:
$167.97
$176.43
52週間の値動き範囲:
$163.33
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
BDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
169.40 | 50.02B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
553.29 | 197.20B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
85.17 | 42.88B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.03 | 36.10B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
29.55 | 15.84B | 11.89B | -560.00M | 191.00M | -1.10 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-05-02 | ダウングレード | Goldman | Buy → Neutral |
| 2025-05-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-05-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | アップグレード | Citigroup | Neutral → Buy |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2023-07-24 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Overweight |
| 2023-05-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-12-12 | アップグレード | Citigroup | Sell → Neutral |
| 2022-07-11 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-06-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | 再開されました | Raymond James | Mkt Perform |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2021-12-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-25 | 開始されました | Barclays | Equal Weight |
| 2020-12-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-06-01 | 再開されました | Goldman | Buy |
| 2020-03-05 | 開始されました | Citigroup | Neutral |
| 2020-02-07 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-02-07 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-01-08 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-05-13 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-12-07 | 開始されました | Deutsche Bank | Buy |
| 2018-10-16 | 開始されました | Barclays | Equal Weight |
| 2018-06-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-04-10 | アップグレード | Citigroup | Neutral → Buy |
| 2018-01-19 | 再開されました | BofA/Merrill | Buy |
| 2018-01-05 | アップグレード | Citigroup | Sell → Neutral |
| 2018-01-05 | 開始されました | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | 開始されました | Evercore ISI | Outperform |
| 2017-12-29 | 繰り返されました | Deutsche Bank | Buy |
すべてを表示
Becton Dickinson Co (BDX) 最新ニュース
Insider Sell: David Shan Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - BD Newsroom
Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com
Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance
AC Health, Becton Dickinson team up to elevate healthcare standards across Asia - Bilyonaryo Business News
Becton Dickinson stock rating cut by Citi to Neutral, target to $185 - Investing.com India
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut b - GuruFocus
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut by Citigroup | BDX Stock News - GuruFocus
6 Analysts Have This To Say About Becton Dickinson - Benzinga
Becton Dickinson (BDX) Downgraded by Citi to Neutral | BDX Stock News - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challen - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challenges | BDX Stock News - GuruFocus
Citigroup Downgrades Becton Dickinson and Co. to Neutral From Buy, Adjusts PT to $185 From $217 - marketscreener.com
BD aims to secure slice of medical technology market - BusinessMirror
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' - BD Newsroom
FBI probes North Canaan suspicious package that contaminated hundreds: What we know and don't know - CT Insider
Becton, Dickinson and Company Stock: Analyst Estimates & Ratings - inkl
Becton, Dickinson And Company Stock: Analyst Estimates & Ratings - Barchart.com
Becton, Dickinson and Company (BDX): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Argus Adjusts Price Target on Becton Dickinson and Co. to $220 From $270, Maintains Buy Rating - marketscreener.com
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Becton Dickinson Sues Baxter Over Infusion Pump Patents - Law360
Becton Dickinson at Bank of America Conference: Navigating Challenges and Opportunities - Investing.com Nigeria
Transcript : Becton, Dickinson and Company Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Judge declares mistrial in punitive damages phase in Walker v. BD - The Covington News
Becton Dickinson Says Baxter Infringes Infusion-Pump Patents (1) - Bloomberg Law News
Sterile Lancets Market Set to Grow | Key Players: Roche, Becton Dickinson, Medtronic - openPR.com
Becton Dickinson (BDX) Unveils Advanced Cell Analyzer - GuruFocus
BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies - marketscreener.com
First Eagle Investment's Strategic Moves: Spotlight on Becton Dickinson & Co - Yahoo Finance
Becton Dickinson & Co (BDX) Shares Up 3.73% on May 12 - GuruFocus
Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts - MSN
The Strong Earnings Posted By Becton Dickinson (NYSE:BDX) Are A Good Indication Of The Strength Of The Business - Yahoo
Morgan Stanley Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $196.00 - Defense World
SEC Form 4 filed by Director Byington Carrie L - Quantisnow
Becton, Dickinson downgraded at more firms following Q2 results - MSN
Becton Dickinson downgraded to Neutral from Buy at Goldman Sachs - MSN
Jim Cramer on Becton, Dickinson and Company (BDX): “A Shocking Miss for This Once-Reliable Med Tech Giant” - Insider Monkey
Mistrial declared after jury awards $50M in landmark toxic gas case - AJC.com
Becton Dickinson (NYSE:BDX) Sees 18% Price Dip Over Last Week - Yahoo Finance
Becton Dickinson (BDX) Price Target Lowered by Morgan Stanley | BDX Stock News - GuruFocus
Investors Can Still File Late Claims for Becton, Dickinson & Co $85M Settlement Payouts - TradingView
Morgan Stanley Adjusts Price Target on Becton, Dickinson and Company to $196 From $280, Maintains Overweight Rating - marketscreener.com
Covington resident wins $20 million in case against Becton Dickinson - The Covington News
Is Becton, Dickinson and Company's (NYSE:BDX) Stock Price Struggling As A Result Of Its Mixed Financials? - simplywall.st
Becton Dickinson Co (BDX) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):